Log in

Molecular mechanisms involved in therapeutic effects of natural compounds against cisplatin-induced cardiotoxicity: a review

  • Review
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

Cisplatin is a widely used chemotherapeutic agent for the treatment of various cancers. However, the clinical use of cisplatin is limited by its cardiotoxic side effects. The primary mechanisms implicated in this cardiotoxicity include mitochondrial dysfunction, oxidative stress, inflammation, and apoptotic. Numerous natural compounds (NCs) have been introduced as promising protective factors against cisplatin-mediated cardiac damage. The current review summarized the potential of various NCs as cardioprotective agents at the molecular levels. These compounds exhibited potent antioxidant and anti-inflammatory effects by interaction with the PI3K/AKT, AMPK, Nrf2, NF-κB, and NLRP3/caspase-1/GSDMD pathways. Generally, the modulation of these signaling pathways by NCs represents a promising strategy for improving the therapeutic index of cisplatin by reducing its cardiac side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

No datasets were generated or analysed during the current study.

Abbreviations

ACC:

Acetyl-CoA carboxylase

ALA:

Alpha-lipoic acid

AMPK:

AMP-activated protein kinase

Apaf-1:

Apoptosis-protease activating factor 1

APO:

Apocynin

ARE:

Antioxidant response element

BACH1:

BTB and CNC homology 1

BAX:

Bcl-2-associated X protein

Bcl-2:

B-cell lymphoma-2

Bzip:

Basic leucine zipper

CAT:

Catalase

COX-2:

Cyclooxygenase-2

CNC:

Cap ‘n’ collar

CUR:

Curcumin

CYN:

Cyaniding

DUBs:

Deubiquitinases

E1:

Ubiquitin-activating enzymes

E2:

Ubiquitin-conjugating enzymes

E3:

Ubiquitin ligases

ELA:

Ellagic acid

ER:

Endoplasmic reticulum

ETC:

Electron transport chain

GCL:

Glutamate cysteine ligase

GPx:

Glutathione peroxidase

GSDMD:

Gasdermin D

GSH:

Glutathione

GSK-3β:

Glycogen synthase kinase-3 beta

GSTs:

Glutathione S-transferases

HES:

Hesperidin

HO-1:

Heme oxygenase-1

ICA:

Icariin

IKK:

IκB kinase

IκB-α:

NF-κB inhibitor-alpha

ILs:

Interleukins

Inos:

Inducible nitric oxide synthase

I/R:

Ischemia/reperfusion

IRF3:

Interferon regulatory factor 3

Keap1:

Kelch-like ECH-associated protein 1

KPF:

Kaempferol

LUT:

Luteolin

LYC:

Lycopene

Maf:

Small musculoaponeurotic fibrosarcoma oncogene

MAL:

Maltol

MCP-1:

Monocyte chemotactic protein-1

MDA:

Malondialdehyde

MOR:

Morphine

NAR:

Naringin

NCs:

Natural compounds

NEK7:

NIMA-related kinase 7

NF-Κb:

Nuclear factor-kappa B

NLRP3:

NOD-like receptor family pyrin domain-containing 3

NQO-1:

NAD(P)H quinone oxidoreductase-1

Nrf2:

Nuclear factor erythroid 2-related factors

p38 MAPK:

P38 mitogen-activated protein kinase

PI3Ks:

Phosphoinositide 3-kinases

PIP2:

Phosphatidylinositol (4,5)-bisphosphate

PIP3:

Phosphatidylinositol (3,4,5)-trisphosphate

QUE:

Quercetin

ROS:

Reactive oxygen species

RSV:

Resveratrol

RUT:

Rutin trihydrate

SA:

Sinapic acid

SalB:

Salvianolic acid B

SAPs:

Saponins

SOD:

Superoxide dismutase

STING:

Stimulator of interferon genes

SYL:

Silymarin

TBK1:

TANK-binding kinase 1

TG:

Tangeretin

TNF-α:

Tumor necrosis factor alpha

TQ:

Thymoquinone

TSC2:

Tuberous sclerosis complex 2

WOG:

Wogonin

ZN:

Zingerone

References

Download references

Acknowledgements

Authors are grateful to the Kermanshah University of Medical Sciences, Health Technology Institute, Medical Biology Research Center, Kermanshah, Iran for financial support.

Funding

This work was supported by the Kermanshah University of Medical Sciences Office of Vice Chancellor for Research, Kermanshah, Iran (Grant numbers: IR.KUMS.REC.1403.021).

Author information

Authors and Affiliations

Authors

Contributions

F.Y. conceived and designed the research. M.H., P.M., and M.M. conducted screening. M.H., P.M., and M.M. extracted data. F.Y. and D.SH. wrote the manuscript. All authors read and approved the manuscript. The authors confirm that no paper mill and artificial intelligence was used.

Corresponding author

Correspondence to Fatemeh Yarmohammadi.

Ethics declarations

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent to publish

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hesari, M., Mohammadi, P., Moradi, M. et al. Molecular mechanisms involved in therapeutic effects of natural compounds against cisplatin-induced cardiotoxicity: a review. Naunyn-Schmiedeberg's Arch Pharmacol (2024). https://doi.org/10.1007/s00210-024-03207-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00210-024-03207-3

Keywords

Navigation